Akoya Biosciences (AKYA) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free AKYA Stock Alerts $2.90 -1.22 (-29.61%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 5:51 PM | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)May 14 at 3:08 PM | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Price Target Cut to $6.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on Akoya Biosciences from $10.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday.May 14 at 9:59 AM | marketwatch.comShares of Akoya Biosciences Drop After 1Q Earnings, Revenue Outlook MissMay 14 at 9:59 AM | finance.yahoo.comAkoya Biosciences Inc (AKYA) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...May 13 at 9:31 PM | investorplace.comAKYA Stock Earnings: Akoya Biosciences Misses EPS, Misses Revenue for Q1 2024May 13 at 4:00 PM | globenewswire.comAkoya Biosciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comAkoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma PatientsMay 8, 2024 | marketbeat.comPeddock Capital Advisors LLC Grows Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA)Peddock Capital Advisors LLC grew its position in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 546.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 290,720 shares of the company's stock after buying an additional 245,728May 6, 2024 | globenewswire.comAkoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, MassachusettsMay 6, 2024 | americanbankingnews.comAkoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on MondayMay 2, 2024 | globenewswire.comAkoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical WorkflowsApril 22, 2024 | globenewswire.comAkoya to Report First Quarter 2024 Financial Results on May 13th, 2024April 16, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 5.9% in MarchAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large decrease in short interest in March. As of March 31st, there was short interest totalling 988,400 shares, a decrease of 5.9% from the March 15th total of 1,050,000 shares. Based on an average daily trading volume, of 203,800 shares, the days-to-cover ratio is currently 4.8 days. Currently, 4.7% of the company's shares are sold short.April 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)April 6, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by Kent Lake Capital LLCKent Lake Capital LLC decreased its holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 84.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,835 shares of the company's stock after selling 629,686 shaApril 5, 2024 | globenewswire.comAkoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and ScaleMarch 23, 2024 | insidertrades.comAkoya Biosciences, Inc. (NASDAQ:AKYA) CEO Brian Mckelligon Sells 7,500 SharesMarch 22, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) CEO Sells $37,275.00 in StockAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) CEO Brian Mckelligon sold 7,500 shares of Akoya Biosciences stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $4.97, for a total value of $37,275.00. Following the sale, the chief executive officer now owns 231,868 shares in the company, valued at $1,152,383.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 17, 2024 | marketbeat.comShort Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Grows By 8.1%Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a significant increase in short interest in the month of February. As of February 29th, there was short interest totalling 835,500 shares, an increase of 8.1% from the February 14th total of 773,200 shares. Approximately 3.9% of the company's shares are sold short. Based on an average daily trading volume, of 209,100 shares, the days-to-cover ratio is presently 4.0 days.March 16, 2024 | uk.investing.comAkoya Biosciences CEO sells $37k worth of sharesMarch 15, 2024 | insidertrades.comInsider Selling: Akoya Biosciences, Inc. (NASDAQ:AKYA) CEO Sells 7,500 Shares of StockMarch 9, 2024 | uk.investing.comAkoya Biosciences Inc (AKYA)March 7, 2024 | marketbeat.comAkoya Biosciences, Inc. Forecasted to Post FY2024 Earnings of ($0.90) Per Share (NASDAQ:AKYA)Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) - Research analysts at Capital One Financial increased their FY2024 earnings per share estimates for shares of Akoya Biosciences in a note issued to investors on Monday, March 4th. Capital One Financial analyst T. Chiang now expects that the comMarch 6, 2024 | seekingalpha.comAkoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | markets.businessinsider.comMassaro Issues Buy Rating for Akoya Biosciences Amid Strong Financial Performance and Market Growth PotentialMarch 6, 2024 | marketbeat.comJPMorgan Chase & Co. Trims Akoya Biosciences (NASDAQ:AKYA) Target Price to $10.00JPMorgan Chase & Co. lowered their target price on Akoya Biosciences from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday.March 6, 2024 | marketbeat.comCapital One Financial Weighs in on Akoya Biosciences, Inc.'s FY2025 Earnings (NASDAQ:AKYA)Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) - Stock analysts at Capital One Financial issued their FY2025 earnings per share estimates for shares of Akoya Biosciences in a report issued on Monday, March 4th. Capital One Financial analyst T. Chiang anticipates that the company will post eaMarch 5, 2024 | finance.yahoo.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) PT Raised to $7.50 at UBS GroupUBS Group boosted their target price on Akoya Biosciences from $7.00 to $7.50 and gave the stock a "buy" rating in a research note on Tuesday.March 5, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy ratingMarch 5, 2024 | marketbeat.comAkoya Biosciences' (AKYA) Buy Rating Reiterated at Canaccord Genuity GroupCanaccord Genuity Group reiterated a "buy" rating and issued a $10.00 target price on shares of Akoya Biosciences in a report on Tuesday.March 5, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Announces Quarterly Earnings ResultsAkoya Biosciences (NASDAQ:AKYA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.05. Akoya Biosciences had a negative return on equity of 121.74% and a negative net margin of 78.14%. During the same period last year, the company posted ($0.50) earnings per share.March 5, 2024 | finanznachrichten.deAkoya Biosciences, Inc.: Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial OutlookMarch 5, 2024 | finance.yahoo.comQ4 2023 Akoya Biosciences Inc Earnings CallMarch 4, 2024 | investorplace.comAKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023March 4, 2024 | benzinga.comRecap: Akoya Biosciences Q4 EarningsMarch 4, 2024 | msn.comAkoya Biosciences GAAP EPS of -$0.22 beats by $0.06, revenue of $26.5M beats by $0.39MMarch 4, 2024 | finance.yahoo.comAkoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 OutlookMarch 4, 2024 | globenewswire.comAkoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial OutlookMarch 3, 2024 | markets.businessinsider.comAkoya Biosciences earnings: here's what to expectMarch 1, 2024 | benzinga.comEarnings Outlook For Akoya BiosciencesFebruary 24, 2024 | finance.yahoo.comAkoya Biosciences Insiders Placed Bullish Bets Worth US$2.11mFebruary 22, 2024 | benzinga.comAkoya Biosciences Stock (NASDAQ:AKYA) Insider TradesFebruary 16, 2024 | finance.yahoo.comRNA Mar 2024 12.500 putFebruary 8, 2024 | finance.yahoo.comAkoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor ConferenceFebruary 7, 2024 | finance.yahoo.comStrength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?January 31, 2024 | benzinga.comAkoya Biosciences Stock (NASDAQ:AKYA) Dividends: History, Yield and DatesJanuary 31, 2024 | finance.yahoo.comBristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority TagJanuary 29, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 13.6% in JanuaryAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 716,800 shares, a growth of 13.6% from the December 31st total of 631,000 shares. Approximately 3.2% of the company's stock are short sold. Based on an average daily volume of 167,200 shares, the days-to-cover ratio is currently 4.3 days.January 26, 2024 | finance.yahoo.comIs Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year? Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. AKYA Media Mentions By Week AKYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKYA News Sentiment▼-0.160.57▲Average Medical News Sentiment AKYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKYA Articles This Week▼142▲AKYA Articles Average Week Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRLD News Today SEER News Today STRO News Today ATHA News Today BNGO News Today NAUT News Today PACB News Today ABUS News Today EYPT News Today QTRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKYA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperHow to Make 100X on the AI BoomInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
